Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203

Related Keywords

Germany ,Texas ,United States ,Houston ,University Hospital ,Martin Wermke ,Cedrik Britten ,Anja Heuer ,Instagramand Linkedin ,Charlotte Spitz ,Immatic Actengine ,University Hospital Dresden ,Twitter ,European Central Bank ,Research Institute Of Texas ,Corporate Communications ,Trophic Communications ,Coordinating Investigator ,Chief Medical Officer ,Safety Monitoring Board ,Overall Response ,Neuroendocrine Tumor ,Best Overall ,All Immatic ,Stem Cell Therapeutics Research Laboratory ,Cancer Prevention ,Research Institute ,Adoptive Cell Therapies ,Looking Statements ,Investor Relations ,Trial Application ,Investigational New Drug ,Immatics ,Reports ,Interim ,Linical ,Data ,Rom ,Ngoing ,Hase ,Cohort ,Monotherapy ,Actengine ,Ma203 ,Targeting ,Frame ,